Quick Facts: Approved Therapeutic Domains

• Chronic Myeloid Leukemia (CML): Used in the management of Philadelphia chromosome positive (Ph+) CML, including newly diagnosed chronic phase and advanced phases.
• Acute Lymphoblastic Leukemia (ALL): Used to address Ph+ ALL in adults and children, often in combination with other therapeutic agents.
• Gastrointestinal Stromal Tumors (GIST): Utilized for Kit (CD117) positive GIST that is unresectable, metastatic, or as adjuvant treatment following surgical resection.
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): Applicable for diseases associated with specific gene rearrangements.
• Other Conditions: Used for aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), and unresectable dermatofibrosarcoma protuberans (DFSP).

---

Imatinib Accord is approved for use in the treatment of a range of hematologic malignancies and certain solid tumors. It is a therapy intended to help manage conditions such as Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) across chronic and advanced stages, in both adult and pediatric patient populations. The medication is also utilized in the therapeutic strategy for Ph+ acute lymphoblastic leukemia (ALL).

Additionally, Imatinib Accord is used to support the care of adult patients diagnosed with Kit-positive gastrointestinal stromal tumors (GIST), including both metastatic disease and as adjuvant treatment after surgery. Further approved uses include addressing myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements. Treatment decisions and duration should be determined by a specialist with experience in managing these specific types of conditions.

Eligibility Map: Who Can and Cannot Use Imatinib Accord

This section summarizes the official population eligibility and exclusion rules based strictly on regulatory documents (FDA, EMA, and national health authorities).

Category	Official Regulatory Statement
Populations Allowed	Adult patients are approved for all labeled indications. Pediatric patients 1 year of age and older are approved for specific leukemias (Ph+ CML and Ph+ ALL).
Contraindicated Populations	Patients with a known hypersensitivity or allergy to imatinib or to any of the product's components are strictly prohibited from use.
Not Recommended/Restricted Use	Pregnancy: Use is generally not recommended due to potential fetal harm; women must use effective contraception during treatment and for a period after the final dose. Lactation: Breastfeeding is not recommended. Severe Renal Impairment: Use is generally not recommended due to insufficient data for establishing a specific dosage.
Conditional Use/Monitoring Required	Hepatic Impairment: Patients with severe hepatic impairment must be started on a reduced initial dosage and monitored closely. Cardiac Risk Factors: Patients with pre-existing cardiac disease or risk factors for congestive heart failure require careful monitoring.
Age Limitations	Safety and efficacy have not been established in children younger than 1 year for approved indications. No specific dose adjustment is required for older adults, but they should be monitored for fluid retention.

---

The eligibility profile is defined by absolute contraindications (hypersensitivity) and prohibitive warnings related to reproductive status (pregnancy/lactation). Use is conditionally allowed for the approved age groups (adults and children 1 year of age), but is subject to official restrictions related to specific comorbidities, particularly impaired hepatic or renal function, which may necessitate initial dose reduction and close clinical observation.

Interactions with other medicines and products

Imatinib Accord's interaction profile is primarily defined by its documented effects on cytochrome P450 (CYP) enzymes, specifically as an inhibitor of CYP3A4/5, CYP2C9, and CYP2D6. This regulatory classification dictates the risk of altered drug exposure for co-administered substances.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Regulatory Outcome/Pattern
Increased Imatinib Levels	Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Grapefruit Juice)	Increase Imatinib plasma exposure (AUC and Cmax)

. | | Decreased Imatinib Levels | Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort) | Decrease Imatinib plasma exposure

. | | Increased Co-drug Levels | CYP3A4/5 and CYP2C9 Substrates | Imatinib inhibits metabolism, increasing the concentration of the co-administered drug. |

Restrictions and Special Considerations

Co-administration with strong CYP3A4 inducers (such as Rifampin, Phenytoin, or Carbamazepine) is officially discouraged due to the risk of reduced Imatinib effectiveness. The strong inhibitory effect on CYP3A4 leads to contraindicated combinations with certain sensitive CYP3A4 substrates, such as Flibanserin and Lomitapide, which have narrow therapeutic indices. Pharmacodynamic interaction exists with Warfarin (a coumarin derivative) which increases the documented risk of bleeding due to combined metabolic and hemostatic effects. The interaction is also heightened in patients with severe hepatic impairment due to increased Imatinib systemic exposure.

Selective Deactivation of Oncogenic Tyrosine Kinases

Imatinib functions as a precise molecular inhibitor by competitively binding to the adenosine triphosphate (ATP) site of specific, overactive protein tyrosine kinases, including the BCR-ABL fusion protein, c-Kit, and PDGFRA/B. By stabilizing the enzyme in its inactive conformation, the drug prevents the transfer of the phosphate group from ATP to substrate proteins (phosphorylation), functionally deactivating the enzyme. This acts within the domains involving receptor- and enzyme-mediated signaling by modulating the activity of the target enzyme.

---

Interruption of Growth and Survival Signaling

The molecular blockade of these key kinases suppresses critical intracellular signaling cascades, specifically those that deliver continuous messages for cell proliferation and anti-apoptotic signaling (e.g., Ras/MAPK and PI3K/AKT pathways). By modifying these early molecular steps, Imatinib initiates a signaling sequence that ultimately leads to two core physiological consequences: the inhibition of cell proliferation and the induction of programmed cell death (apoptosis) in the cells dependent on the abnormal kinase. This results in the modulation of cell populations carrying the molecular defect.

---

Mechanistic Limitations: The Role of Mutations

The effectiveness of this targeted mechanism can be constrained by acquired resistance, which commonly involves the development of point mutations within the kinase domain of the target protein. These mutations alter the shape of the ATP-binding pocket, preventing Imatinib from binding with sufficient affinity and thereby overriding its inhibitory action.

How Imatinib Accord is Used: Official Administration Guidelines

Imatinib Accord is supplied as a film-coated tablet intended for oral administration, offering a high degree of convenience for long-term treatment protocols. The administration is strictly required to be meal-dependent; each prescribed dose must be consumed with a meal and a large glass of water to minimize potential gastrointestinal discomfort and ensure optimal intake.

---

Dosing and Frequency Patterns

The standard starting dose is determined by the specific condition being addressed, ranging from 100 mg to 800 mg daily. For adult patients, typical starting doses are 400 mg or 600 mg daily for conditions like Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST).

Administration Pattern	Description
Frequency	Typically administered once daily (QD).
High-Dose Split	A total daily dose of 800 mg must be divided and administered as 400 mg twice a day (BID), in the morning and evening, respectively.

---

Administration Details and Course Duration

Tablets should be swallowed whole. For patients who cannot swallow, the official instructions permit dissolving the tablets in a specific volume of still water or apple juice and drinking the suspension immediately.

Treatment duration is generally continuous and long-term, continuing until there is evidence of disease progression or unacceptable toxicity. However, for conditions like adjuvant GIST following surgical resection, the treatment course is explicitly recommended for three years.

For pediatric patients, the dose is calculated based on Body Surface Area (BSA), and high-level adjustments, such as dose reduction, are specified in the label for patients with severe hepatic impairment.

Research Evidence / Overview of Studies for Imatinib Accord

Evidence for use in Chronic Myeloid Leukemia (CML)

Research for Chronic Myeloid Leukemia (CML) includes pivotal, large-scale Randomized Controlled Trials (RCTs) that compared this medicine against comparator treatments, along with extensive long-term observational extension studies. These studies monitored overall survival and measured cytogenetic and molecular response patterns in newly diagnosed patients. Findings describe patterns where measurements of molecular and cytogenetic response were reported in the observed populations.

Despite the volume of available data, certainty remains low regarding direct comparisons of long-term overall survival due to a high rate of patient crossover in the initial pivotal trials. Research is ongoing to fully characterize the durability of molecular response and to examine the clinical characteristics of acquired resistance that was observed in some studies.

---

Evidence for use in Gastrointestinal Stromal Tumors (GIST)

The evidence landscape for Gastrointestinal Stromal Tumors (GIST) includes multiple RCTs, evaluated in both advanced (metastatic) disease and the post-operative (adjuvant) setting. These studies monitored Progression-Free Survival (PFS) and Recurrence-Free Survival (RFS). Findings describe patterns where lower recurrence rates were measured for certain high-risk patients observed at three years compared to one year in the adjuvant trials. Research exploring short-term changes is well-documented, but subgroup findings are uncertain concerning the optimal duration of therapy for all molecularly-defined subsets of GIST.

---

Evidence for Rare, Molecularly Defined Conditions and Research Gaps

Evidence for rare conditions, such as Ph+ Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic/Myeloproliferative Diseases (MDS/MPD), relies mainly on smaller, single-arm Phase 2 studies in molecularly specific patient cohorts. Evidence quality varies across studies, and comparative evidence is lacking for many of these rare indications.

Research was studied for pediatric and older adult patients, but follow-up durations were limited in initial studies for children. The overall research highlights the need for continued observation, as long-term effects are not fully established regarding durability of response when treatment is intentionally stopped, and reliance on surrogate endpoints remains a major limitation.

Key Studies & References

1. Imatinib Mesylate: An Overview

Common questions about Imatinib Accord (FAQ)

Q: What is the main reason Imatinib Accord is prescribed?

A: Imatinib Accord is a targeted therapy approved by regulatory bodies to treat certain types of cancer. These include Philadelphia chromosome positive Chronic Myeloid Leukemia (Ph+ CML) and Ph+ Acute Lymphoblastic Leukemia (ALL). It is also used to treat specific types of Gastrointestinal Stromal Tumors (GIST), among other conditions described in official documents.

---

Q: Does Imatinib Accord interact with common over-the-counter pain relievers?

A: Official drug information highlights that Imatinib can be affected by medicines that interact with specific liver enzymes, known as Cytochrome P450 (CYP) enzymes. Imatinib is classified as both a substrate and inhibitor of multiple CYP enzymes. Regulatory information indicates that consultation with a healthcare professional regarding all over-the-counter pain relievers is important, as some may alter the concentration of Imatinib in the body.

---

Q: How long does it usually take to feel or see the effects of Imatinib Accord?

A: Evidence from clinical studies has explored the timelines for initial responses in patient populations. For newly diagnosed chronic phase CML, evidence indicates that complete hematologic responses (changes in blood cell counts) were typically observed within the first four weeks of therapy. However, monitoring long-term results involves molecular and cytogenetic changes which take longer.

---

Q: If I miss a dose of Imatinib Accord, what is the general guidance?

A: According to the official patient information, if a dose is forgotten, the recommendation is to take it as soon as it is remembered. If it is almost time for your next scheduled dose, the regulatory guidance is to skip the missed dose entirely. Official guidance advises against taking a double dose to compensate for a missed dose; instead, administration should continue with the regular schedule.

---

Q: Can men use Imatinib Accord if they plan on fathering a child?

A: Official product information contains limited data specifically on the effects of this medicine on male fertility. While the labeling primarily focuses on restrictions related to pregnancy in women, regulatory documents state that patients who are concerned about fertility while using this medicine should seek discussion with their healthcare provider.

---

Q: Does Imatinib Accord make you feel tired or fatigued?

A: Official drug safety documents indicate that tiredness (fatigue) is a reported adverse reaction of the medicine. This symptom is classified as a very common adverse reaction, meaning it is reported in 10% or more of patients in clinical studies.

---

Q: Can I drive or operate machinery while taking Imatinib Accord?

A: The official product information includes warnings about potential effects on the ability to drive. This medicine may cause certain side effects, such as dizziness, drowsiness, or blurred vision. If these effects occur, official guidance suggests avoiding driving or operating complex machinery until the symptoms have resolved.

---

Q: Is it possible to develop a rash from Imatinib Accord?

A: Regulatory documents indicate that a rash is a possible adverse reaction. A rash is listed as a very common side effect, occurring in 10% or more of patients. Official information also notes that severe skin reactions have been reported in some cases.

---

Q: Do patients typically gain or lose weight on Imatinib Accord?

A: Official product information states that weight gain is a common side effect, which is reported in 1% to 10% of patients. This weight gain may be related to fluid retention, which is a very common adverse reaction. Weight gain that is sudden or significant should be brought to the attention of a healthcare provider.

---

Q: Are there different strengths of Imatinib Accord available?

A: According to the official composition documents, this medicine is manufactured in different tablet strengths. Imatinib Accord is available as a 100 mg film-coated tablet and a 400 mg film-coated tablet.

---

Q: What if I need to have surgery? Should I stop Imatinib Accord?

A: The decision to stop treatment before or after surgery is a clinical one that must be made by the treating physician. The product information does note that certain medications, such as blood thinners like Warfarin, interact with Imatinib and may increase the risk of bleeding, which is a key consideration during surgery.

---

Q: What is the risk of skin darkening or pigmentation changes with Imatinib Accord?

A: Regulatory sources indicate that pigmentation changes are a possible, though less frequent, side effect. Skin darkening is classified as an uncommon adverse reaction, occurring in 0.1% to 1% of patients.

---

Q: Is Imatinib Accord known to cause headaches?

A: Headache is an adverse reaction reported in the official safety documents for the medicine. This symptom is categorized as a very common side effect, meaning it was reported by 10% or more of patients in clinical studies.

---

Q: How long has Imatinib been used in medical treatment?

A: The active substance, Imatinib, has been a key component in cancer treatment for a significant period. Regulatory bodies initially approved the original reference product for this medicine in 2001.

---

Q: Can Imatinib Accord cause changes in mood or sleep?

A: Regulatory documents have reported that the medicine can sometimes be associated with changes in mood and sleep patterns. Specifically, difficulty sleeping (insomnia) and other mood changes have been listed as possible side effects in the official product information.

How to Store and Dispose of Imatinib Accord

Imatinib Accord tablets must be stored strictly according to the official regulatory guidelines to maintain product quality and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 30°C (or mathbf25^circC as per specific regional labeling).
Packaging	Keep in the original container or blister pack. Do not use after the expiry date (EXP).
Safety	Must be kept out of the sight and reach of children.

---

Disposal Instructions

Medicines should not be disposed of via wastewater or with household waste. Unused or expired Imatinib Accord must be returned to a pharmacist or a designated pharmaceutical waste collection point. Disposal must adhere to local requirements for pharmaceutical waste to protect the environment.